RADNOR, Pa., Aug. 28, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nati

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $EYPT--EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

RADNOR, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating pot

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recogn

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW

EyePoint Pharmaceuticals shares opened down approximately 70% after the Company disclosed that DURAV

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.

DURAVYU's Phase 3 LUGANO trial missed its prespecified primary endpoint, and EYPT shares lost nearly

Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common st

NEW YORK--(BUSINESS WIRE)--Roughly seven out of every ten dollars invested in EyePoint Pharmaceutica

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involvin

Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD f

Eyepoint Pharmaceuticals (NASDAQ: EYPT) reported topline results from LUGANO, the first of two Phase

EyePoint Inc. (NASDAQ:EYPT) on Monday released topline results from its pivotal Phase 3 LUGANO clini

EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoin

Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the pr

EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but s

EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transc

RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perfo

Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral a

Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD trea

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's reg

Jefferies analyst Kambiz Yazdi maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price t

US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consu

EyePoint Inc. (NASDAQ:EYPT) stock plunged on Monday after the company released topline results from

EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden de

US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech

Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-mar

EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative thera

– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc a

Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed

Cantor Fitzgerald analyst Steve Seedhouse maintains EyePoint (NASDAQ:EYPT) with a Overweight and

HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers th

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed t

Wall Street analysts change outlook on top names. Check out analyst ratings page for upgrades, downg

Stifel analyst Annabel Samimy initiates coverage on EyePoint (NASDAQ:EYPT) with a Buy rating and

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cantor Fitzgerald analyst Steve Seedhouse assumes EyePoint (NASDAQ:EYPT) with a Overweight rating

Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ:EYPT) with a Buy and raises

RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Outperform and lowers the

On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeut

Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and raises the pr

Summary:Top Wall Street analysts changed outlook on top names. Analyst ratings page shows all chang

HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and raises th